June 8, a long-term contract was signed by Russian Company Geropharm and the Karaganda Pharmaceutical Complex during the exhibition “Eurasia is Our Home”. According to the plan, the Russian pharmaceutical company will produce glargine “RinGlar” 200 IU/ml, which is an analogue of long-acting insulin.
According to the terms of the contract, Geropharm will transfer its technology to Kazakhstan, and the Kazakh company will invest in the modernization of the production facility. The insulin substance will be supplied from the Geropharm’s facility in St. Petersburg.
In 2020, Geropharm have introduced glargine 100 IU/ml to Kazakhstan. The transfer of technology for the production of insulin at a higher concentration will allow patients with type 1 or type 2 diabetes to use higher doses of insulin to reduce the volume of injections administered. According to experts, the country’s need for this insulin is about 120,000 packs per year.
“We have already received a registration certificate for glargine at a dosage of 300 IU/ml under the EAEU procedure. But the operation of the “evergreen” patent, which artificially prolongs the monopoly of foreign pharmaceutical companies in our market, and which we have been fighting for several years, does not allow the production and release of the drug for Russian patients. There is no such a thing in Kazakhstan, so the medicine can be available to patients,” commented Petr Rodionov, General Director of Geropharm, commenting on the conclusion of the agreement.